A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)
Latest Information Update: 16 Oct 2025
At a glance
- Drugs Finerenone (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Bayer
Most Recent Events
- 05 Oct 2025 New trial record